Company news
Bioporto A/s (OMXCOP:BIOPOR) news
Every Bioporto A/s press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
First Patient In - BioPorto Initiates Patient Enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study.
September 16, 2026
BioPorto announces Interim Results for the Second Quarter and First half of 2026
August 20, 2026
BioPorto A/S to host an investor webcast on the results for the first half of 2026
August 12, 2026
BioPorto announces Interim Result for the First Quarter of 2026
May 21, 2026
Resolutions of the Annual General Meeting
April 24, 2026
Grant of Warrants
April 14, 2026
Major Shareholder Announcement
April 13, 2026
BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC
April 8, 2026
BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis
March 31, 2026
Notice convening the Annual General Meeting in BioPorto A/S
March 26, 2026
BioPorto announces the Annual Report for 2025
March 26, 2026
BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026
March 18, 2026
BioPorto A/S Appoints Chief Financial Officer
February 9, 2026
BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update
February 5, 2026
Changes to the Executive Management
December 11, 2025
Managers’ transactions
November 24, 2025
BioPorto A/S raises approximately DKK 43 million in new capital round - Change in number of shares and votes
November 24, 2025
BioPorto Interim Result for the Third Quarter of 2025 – Continued progress and continued NGAL sales growth
November 19, 2025
Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S
November 13, 2025
BioPorto Executes on its Financing Strategy- BioPorto A/S initiates pre-subscribed private placement
November 13, 2025
Business Strategy Update – the “Forward” Strategic Direction, Aspirations towards 2028 and Funding Needs
November 4, 2025
Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025
November 4, 2025
Progress Update on BioPorto’s Adult Clinical Study
November 4, 2025
BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented
September 26, 2025
US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker
September 11, 2025
ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics.
August 28, 2025
BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth.
August 15, 2025
BioPorto A/S to host an investor webcast on the results for the first half of 2025
July 29, 2025
BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.
July 28, 2025
Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US
June 27, 2025
BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy
June 10, 2025
Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained.
May 8, 2025
BioPorto A/S to host first quarter 2025 earnings webcast for investors
April 28, 2025
BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million
April 25, 2025
BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes
April 25, 2025